CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 18, 2014
Result type: Reports
Project Number: SR0397-000
Product Line: Reimbursement Review

Generic Name: Apixaban

Brand Name: Eliquis

Manufacturer: Bristol-Myers Squibb Canada and Pfizer Canada Inc. Alliance

Therapeutic Area: Venous thromboembolic events, treatment and prevention of recurrence

Indications: Thromboembolic events (venous), treatment and prevention of recurrence

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 7, 2015

Recommendation Type: List with clinical criteria and/or conditions